AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25834276 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique
Number of subjects: 72
Study 25834276 — intervention group
Group type: COMPARATOR
Intervention: Local heat application
Number of subjects: 72
Study 25834276 — intervention group
Group type: COMPARATOR
Intervention: Guided imagery
Number of subjects: 72
Study 24033830 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed shock at 20 ms before peak (Group I)
Number of subjects: 200
Study 24033830 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed shock at peak (Group II)
Number of subjects: 200
Study 24033830 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed shock at 20 ms after peak (Group III)
Number of subjects: 200
Study 22170706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced β-endorphin levels above 25 pg/ml (n = 7)
Number of subjects: 16
Study 20158290 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 mg/70 kg)
Number of subjects: 20
Study 20158290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.40, 0.80 g/kg)
Number of subjects: 20
Study 20158290 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 20
Study 20158290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study 18514870 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 braided cables
Number of subjects: 9
Study 18514870 — intervention group
Group type: COMPARATOR
Intervention: 2 braided cables
Number of subjects: 9
Study 16872896 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Lavasept solution (n=28)
Number of subjects: 50
Study 16872896 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution (n=22)
Number of subjects: 50
Study 15641497 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum (65% xylitol), 6 pieces daily for 14 days
Number of subjects: 10
Study 15641497 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol-containing chewing gum (control), 6 pieces daily for 14 days
Number of subjects: 10
Study 10604694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardex I.C. hydrogel/silver-coated Foley catheter
Number of subjects: 5
Study 10604694 — intervention group
Group type: COMPARATOR
Intervention: Standard latex Foley catheter
Number of subjects: 5
Study 7780067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine infusion
Number of subjects: 0
Study 7780067 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA meperidine infusion
Number of subjects: 0
Study 2277298 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and steroids with 28 days of intravenous antithymocyte globulin
Number of subjects: 275
Study 2277298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and low-dose steroids
Number of subjects: 275
Study 2277298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and azathioprine
Number of subjects: 275
Study 2277298 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (not specified)
Number of subjects: 275
Study 2277298 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 275
Study 416647 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum external megavoltage irradiation, 5,000 rads
Number of subjects: 302
Study 416647 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose irradiation, 3,000 rads followed by chemotherapy with Thio‐tepa
Number of subjects: 302
Study 31727073 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement approach for recruitment and retention
Number of subjects: 722
Study 28691417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied during PCI at a dose of 9 J/cm2
Number of subjects: 52
Study 28691417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 52
Study 28691417 — intervention group
Group type: COMPARATOR
Intervention: Control group (PCI only)
Number of subjects: 52
Study 26435259 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gaming with food and drink offered ad libitum
Number of subjects: 21
Study 26435259 — intervention group
Group type: COMPARATOR
Intervention: Seated gaming with food and drink offered ad libitum
Number of subjects: 21
Study 26435259 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gaming (no food or drink)
Number of subjects: 21
Study 26435259 — intervention group
Group type: COMPARATOR
Intervention: Seated gaming (no food or drink)
Number of subjects: 21
Study 23321244 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)(2)) paste
Number of subjects: 0
Study 23321244 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (deionized water)
Number of subjects: 0
Study 23321244 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (bipaste)
Number of subjects: 0
Study 23321244 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (tripaste)
Number of subjects: 0
Study 22129567 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (ferrous succinate, 200 mg [100 mg × 2])
Number of subjects: 20
Study 22129567 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Sulifei, 200 mg [100 mg × 2])
Number of subjects: 20
Study 22129567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 19620517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (50 mmol/24 hours x 7 days)
Number of subjects: 12
Study 19620517 — intervention group
Group type: COMPARATOR
Intervention: High sodium diet (250 mmol/24 hours x 7 days)
Number of subjects: 12
Study 16387501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 109
Study 16387501 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 109
Study 15663236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine mesylate (15 ml of 8.94 mg/ml for anesthesia and 2.374 mg/ml for analgesia)
Number of subjects: 44
Study 15663236 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine hydrochloride (15 ml of 7.5 mg/ml for anesthesia and 2 mg/ml for analgesia)
Number of subjects: 44
Study 11243638 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene gloves
Number of subjects: 8
Study 11243638 — intervention group
Group type: COMPARATOR
Intervention: Poorest glove
Number of subjects: 8
Study 9060078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral adrenalectomy
Number of subjects: 40
Study 9060078 — intervention group
Group type: COMPARATOR
Intervention: No ipsilateral adrenalectomy (Control)
Number of subjects: 40
Study 8360732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 33
Study 8360732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 3521798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 100
Study 3521798 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 100
Study 29066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Precommitment intervention with decision supports and reminders for Choosing Wisely recommendations
Number of subjects: 45
Study 29066616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no precommitment intervention)
Number of subjects: 45
Study 29066616 — intervention group
Group type: COMPARATOR
Intervention: 3-month postintervention follow-up
Number of subjects: 45
Study 27640187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including smoke-free school grounds, smoke-free curriculum, and parental involvement.
Number of subjects: 4161
Study 27640187 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no specific intervention details provided).
Number of subjects: 4161
Study 23968972 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-soled shoe (Shore A25)
Number of subjects: 35
Study 23968972 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-soled shoe (Shore A40)
Number of subjects: 35
Study 23968972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-soled shoe (Shore A58)
Number of subjects: 35
Study 23968972 — intervention group
Group type: COMPARATOR
Intervention: All shoe conditions
Number of subjects: 35
Study 23782995 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpartum home biofeedback physiotherapy
Number of subjects: 120
Study 23782995 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises (PFEs)
Number of subjects: 120
Study 20839572 — intervention group
Group type: EXPERIMENTAL
Intervention: Placentrex injection combined with antimicrobial therapy (Group I)
Number of subjects: 100
Study 20839572 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy alone (Group II)
Number of subjects: 100
Study 18823261 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong practice
Number of subjects: 37
Study 18823261 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 37
Study 16473983 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 30
Study 16473983 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study 16473983 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 30
Study 12072632 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 86
Study 12072632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scissors hemorrhoidectomy
Number of subjects: 86
Study 12072632 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy (scissors excision‐ligation technique)
Number of subjects: 86
Study 10604829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral capsules, 5 mg/kg twice a day for 12 weeks
Number of subjects: 96
Study 10604829 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SIM) capsules, 5 mg/kg twice a day for 12 weeks
Number of subjects: 96
Study 10604829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral capsules
Number of subjects: 96
Study 8942775 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal-occult-blood (FOB) screening
Number of subjects: 150251
Study 8942775 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 150251
Study 1663301 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A virus vaccine
Number of subjects: 0
Study 1663301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aluminium hydroxide)
Number of subjects: 0
Study 6752738 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.0, 0.125, 0.25, and 0.5 mg given intravenously over 30 min)
Number of subjects: 10
Study 6752738 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 6752738 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 10
Study 31918946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent (RES)
Number of subjects: 2221
Study 31918946 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2221
Study 29180278 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg
Number of subjects: 104
Study 29180278 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg
Number of subjects: 104
Study 26694499 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-ESA (TE)
Number of subjects: 36
Study 26694499 — intervention group
Group type: COMPARATOR
Intervention: Sedentary-ESA (SE)
Number of subjects: 36
Study 26694499 — intervention group
Group type: COMPARATOR
Intervention: Training-Placebo (TP)
Number of subjects: 36
Study 24732230 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Seldinger technique (AST)
Number of subjects: 0
Study 24732230 — intervention group
Group type: COMPARATOR
Intervention: Modified Seldinger technique (MST)
Number of subjects: 0
Study 22210925 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (lipase inhibitor)
Number of subjects: 21
Study 22210925 — intervention group
Group type: COMPARATOR
Intervention: No Orlistat
Number of subjects: 21
Study 22210925 — intervention group
Group type: EXPERIMENTAL
Intervention: CD36 genotype (AA, AG, GG)
Number of subjects: 21
Study 21351255 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length adiponectin treatment
Number of subjects: 0
Study 21351255 — intervention group
Group type: COMPARATOR
Intervention: AdipoR1 and AdipoR2 expression levels
Number of subjects: 0
Study 21351255 — intervention group
Group type: COMPARATOR
Intervention: AdipoR1 and AdipoR2 immunostaining
Number of subjects: 0
Study 21351255 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray analysis
Number of subjects: 0
Study 18036907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (titrated intravenous insulin infusion)
Number of subjects: 44
Study 18036907 — intervention group
Group type: COMPARATOR
Intervention: Standard high-dose systemic insulin infusion at 5 mU/kg/min
Number of subjects: 44
Study 16286438 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg daily)
Number of subjects: 30
Study 16286438 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 12128237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg)
Number of subjects: 50
Study 12128237 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 50
Study 9823789 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic regimens (bolus thrombolysis, glycoprotein IIb/IIIa inhibition, low‐molecular‐weight heparin)
Number of subjects: 0
Study 9823789 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibition
Number of subjects: 0
Study 9823789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin
Number of subjects: 0
Study 9823789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering with statin drugs
Number of subjects: 0
Study 9823789 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 8043977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment for 12 weeks
Number of subjects: 11
Study 8043977 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 11
Study 3377212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42% NaHCO3 solution added to bupivacaine
Number of subjects: 40
Study 3377212 — intervention group
Group type: COMPARATOR
Intervention: Normal saline added to bupivacaine
Number of subjects: 40
Study 31573392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glissonean pedicle transection with hepatic vein exclusion (Glisson group, n = 25)
Number of subjects: 50
Study 31573392 — intervention group
Group type: COMPARATOR
Intervention: Pringle maneuver with intermittent clamping (Pringle group, n = 25)
Number of subjects: 50
Study 29174310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg once daily for 24 months)
Number of subjects: 222
Study 29174310 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (vinorelbine 25 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for four cycles)
Number of subjects: 222
Study 29174310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 222
Study 29174310 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin
Number of subjects: 222
Study 27464735 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with Accident Reactions (CARE) intervention
Number of subjects: 0
Study 27464735 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 25437581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-port LC using SILS
Number of subjects: 3
Study 25437581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-port LC using a laparoscope with a working channel
Number of subjects: 3
Study 25437581 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-port LC using standard ports
Number of subjects: 3
Study 25437581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 3
Study 22878176 — intervention group
Group type: EXPERIMENTAL
Intervention: L5-S1 HVLA spinal manipulation (SM) procedure
Number of subjects: 66
Study 22878176 — intervention group
Group type: COMPARATOR
Intervention: L5-S1 joint pre-loading procedure
Number of subjects: 66
Study 22878176 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 66
Study 20151469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 200
Study 20151469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18501565 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 42
Study 18501565 — intervention group
Group type: COMPARATOR
Intervention: Non-patient control group
Number of subjects: 42
Study 16392989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 92
Study 16392989 — intervention group
Group type: COMPARATOR
Intervention: Stress management and wellness (SMW) training
Number of subjects: 92
Study 16281510 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/d) and acetyl-L-carnitine (1 g/d)
Number of subjects: 150
Study 16281510 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (100 mg) plus Vitamin C (100 mg)
Number of subjects: 150
Study 11057854 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) concentrates
Number of subjects: 133
Study 11057854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 9121974 — intervention group
Group type: COMPARATOR
Intervention: Transvenous lead alone
Number of subjects: 267
Study 9121974 — intervention group
Group type: COMPARATOR
Intervention: Transvenous lead linked to a patch electrode
Number of subjects: 267
Study 9121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous lead linked to the investigational array electrode
Number of subjects: 267
Study 8489061 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 0 cmH2O
Number of subjects: 6
Study 8489061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 5 cmH2O
Number of subjects: 6
Study 8489061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cmH2O
Number of subjects: 6
Study 3552909 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 1-2 g
Number of subjects: 27
Study 3552909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3552909 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 27
Study 2680430 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 360 mg/day)
Number of subjects: 74
Study 2680430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31720916 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturable microbial diversity from salterns
Number of subjects: 190
Study 31720916 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular screening for biosynthetic genes
Number of subjects: 190
Study 31720916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of amplicons
Number of subjects: 190
Study 31027963 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive (information, self‐exercise, occlusal splints)
Number of subjects: 24
Study 31027963 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive (information, arthrocentesis with lavage, manipulation, postoperative self‐exercise)
Number of subjects: 24
Study 28906574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of picosecond laser (1 064 and 595 nm) and 2% hydroquinone (HQ) cream for 7 weeks and 5 weeks of laser treatment (weekly).
Number of subjects: 78
Study 28906574 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroquinone (HQ) cream alone for 7 weeks.
Number of subjects: 78
Study 28906574 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond laser treatment side at week 7.
Number of subjects: 78
Study 28906574 — intervention group
Group type: COMPARATOR
Intervention: Control side (2% HQ alone) at week 7.
Number of subjects: 78
Study 25920470 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training involving the less-affected side (MTLA)
Number of subjects: 35
Study 25920470 — intervention group
Group type: COMPARATOR
Intervention: Neurophysiological-based conventional therapy
Number of subjects: 35
Study 23439301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon with ribavirin
Number of subjects: 114
Study 23439301 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon without ribavirin
Number of subjects: 114
Study 21742943 — intervention group
Group type: EXPERIMENTAL
Intervention: Algae‐derived DHA (12 g·ewe(‐1)·d(‐1))
Number of subjects: 80
Study 21742943 — intervention group
Group type: COMPARATOR
Intervention: Control (no algae‐derived DHA)
Number of subjects: 80
Study 21742943 — intervention group
Group type: EXPERIMENTAL
Intervention: Algae‐derived DHA
Number of subjects: 80
Study 21742943 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 20003384 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sex counselling
Number of subjects: 450
Study 20003384 — intervention group
Group type: COMPARATOR
Intervention: Intensive sexological treatment
Number of subjects: 450
Study 20003384 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (waiting list)
Number of subjects: 450
Study 17100679 — intervention group
Group type: EXPERIMENTAL
Intervention: AV sequential pacing mode
Number of subjects: 72
Study 17100679 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing mode
Number of subjects: 72
Study 17100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 72
Study 16097633 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide stress
Number of subjects: 0
Study 11262572 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy (O2)
Number of subjects: 26
Study 11262572 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 26
Study 11262572 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive bilevel positive pressure ventilation
Number of subjects: 26